Publicaciones científicas

Biomarker counselling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer´s Disease Consortium survey

07-sep-2020 | Revista: International Journal of Geriatric Psychiatry

Kristian Steen Frederiksen  1 , T Rune Nielsen  1 , Ildebrando Appollonio  2 , Birgitte Bo Andersen  1 , Mario Riverol  3 , Mercè Boada  4   5 , Mathieu Ceccaldi  6 , Bruno Dubois  7 , Sebastiaan Engelborghs  8   9 , Lutz Frölich  10 , Lucrezia Hausner  10 , Audrey Gabelle  11 , Tomasz Gabryelewicz  12 , Timo Grimmer  13 , Bernard Hanseeuw  14 , Jakub Hort  15 , Jacques Hugon  16 , Vesna Jelic  17 , Anne Koivisto  18   19 , Milica G Kramberger  20 , Thibaud Lebouvier  21 , Alberto Lleó  22 , Alexandre de Mendonça  23 , Flavio Nobili  24   25 , Pierre-Jean Ousset  26 , Robert Perneczky  27   28   29   30 , Marcel Olde Rikkert  31 , David Robinson  32 , Olivier Rouaud  33 , Elisabet Sánchez  34 , Isabel Santana  35   36 , Nikolaos Scarmeas  37   38 , Katerina Sheardova  39 , Stephanie Sloan  40 , Luiza Spiru  41   42 , Elka Stefanova  43 , Latchezar Traykov  44 , Görsev Yener  45 , Gunhild Waldemar  1


Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counselling, management, and follow-up in European expert centers diagnosing patients with MCI.

Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's Disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; Southern Europe: 15 centers) with questions on attitudes towards biomarkers and biomarker counselling in MCI and dementia. This included post-biomarker counselling and the process of diagnostic disclosure of MCI, as well as treatment and follow-up in MCI.

Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre- and post-biomarker counselling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI.

Conclusions: The variability in clinical practices across centers calls for better biomarker counselling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning.

CITA DEL ARTÍCULO  Int J Geriatr Psychiatry. 2020 Sep 7. doi: 10.1002/gps.5427

Nuestros autores

COVID-19